The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression.
• miR-1-3p, a member of the miRNA-1 family, is recognized as a tumor suppressor in various cancers.
• The specific role and regulatory mechanisms of miR-1-3p in prostate cancer (PCa) remain largely unexplored.

Purpose of the Study:

• To investigate the expression levels and biological functions of miR-1-3p in prostate cancer.
• To elucidate the molecular mechanisms underlying miR-1-3p's role in PCa progression.
• To assess the potential of miR-1-3p as a prognostic biomarker and therapeutic target for PCa.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (RT-qPCR) and bioinformatics analyses were employed to determine miR-1-3p expression in PCa cell lines and tissues.
• In vitro and in vivo functional assays were conducted to evaluate the effects of miR-1-3p on tumor cell growth and cell cycle progression.
• Luciferase reporter assays were utilized to confirm the direct targeting of E2F5 and PFTK1 by miR-1-3p.

Main Results:

• miR-1-3p was found to be significantly downregulated in advanced PCa tissues and cell lines, correlating with aggressive clinicopathological features and poor patient prognosis.
• Overexpression of miR-1-3p suppressed tumor cell proliferation and cell cycle progression both in vitro and in vivo.
• miR-1-3p directly targets the 3'-untranslated region (3'-UTR) of E2F5 and PFTK1, leading to decreased expression of these cell cycle regulatory genes.

Conclusions:

• miR-1-3p plays a crucial role in regulating cell proliferation and cell cycle progression in prostate cancer.
• The downregulation of miR-1-3p contributes to the molecular etiology of PCa.
• miR-1-3p holds promise as a potential biomarker for PCa prognosis and a therapeutic target for PCa treatment.